NMPA Releases Draft Measures on Market Exclusivity for Pediatric & Orphan Drugs

On October 19, 2026, the General Department of China’s National Medical Products Administration (NMPA) published the Implementation Measures on Drug Market Exclusivity (Draft for Comments) for public consultation. The draft provides detailed implementation rules for Article 21 of the revised Regulations for Implementation of the Drug Administration Law, which introduced market exclusivity of up to two years for qualifying pediatric drugs and seven years for rare disease drugs.

For multinational pharmaceutical companies, the implications extend beyond regulatory compliance: eligibility, clinical evidence, filing timelines, and commercial supply commitments will all influence the ability to secure and retain market protection in China.

Moving From Statutory Framework to Operational Enforcement

Following the introduction of market exclusivity under the revised Implementing Regulations in May 2026, the proposed measures provide further clarity on eligibility criteria, exclusivity periods, application procedures, and implementation requirements. This allows pharmaceutical developers to better assess potential protection and incorporate exclusivity considerations a into their China regulatory and commercial strategies.

Three Strategic Considerations for Pharmaceutical Developers

 The proposed measures provide further clarity on how market exclusivity may affect pharmaceutical development and registration strategies in China. For international applicants, three key considerations emerge:

1. Qualification Standards for Pediatric & Orphan Drugs

 Eligibility for market exclusivity depends on the drug category, registration pathway, and applicable regulatory requirements.

• Pediatric Drugs: Market exclusivity of up to two years is available for qualifying innovative drugs developed for pediatric use, while certain new pediatric indications, dosage forms, and strengths may qualify for one year of protection. Applicants must demonstrate that their products meet the relevant pediatric eligibility criteria.
• Rare Disease Drugs: Market exclusivity of up to seven years is available for qualifying rare disease therapies, with shorter periods of five or four years applicable to certain other registration categories. Eligibility depends on the drug classification, approved indication, and relevant regulatory criteria.

2. Linking Market Protection to Reliable Product Supply

For rare disease drugs, the draft also connects exclusivity to commercial availability. Under Article 18, applicants must commit to maintaining a stable supply of the product. Failure to meet supply obligations, absent force majeure, may result in early termination of exclusivity and allow generic approvals to proceed sooner.

This introduces a commercial consideration into exclusivity planning: securing protection is only part of the challenge. Sponsors must also establish that their manufacturing, distribution, and supply arrangements can support continued availability in China. Global supply strategies should therefore be assessed against local obligations before launch.

3. Coordinating Exclusivity Applications with Global Filing Timelines

The draft rules emphasize coordinated regulatory timing. Because exclusivity applications must be submitted concurrently with the initial marketing authorization filing, multinational companies benefit from integrating their regional submission planning early into their global development schedules to avoid missing the single-application window.

Sponsors should therefore incorporate China-specific eligibility assessments and exclusivity documentation into global regulatory planning well before filing. Waiting until the marketing authorization dossier is finalized could leave insufficient time to address the requirements within the prescribed application window.

Recommended Actions During the Consultation Period

With the regulatory landscape progressing, pharmaceutical teams have a valuable opportunity to engage with the regulatory process before the public comment window closes on November 18, 2026:

• Conduct a Pipeline Review: Screen current clinical-stage assets against the draft eligibility criteria to identify potential candidates for pediatric or orphan drug exclusivity.
• Perform Data and Evidence Assessments: Review existing clinical packages to ensure they effectively substantiate the therapeutic benefits for targeted patient cohorts and address local unmet clinical needs.
• Participate in Public Consultation: Collaborate through industry associations or regulatory counsel to submit constructive technical feedback to the NMPA (via hxypc@nmpa.gov.cn) regarding definitions, supply obligation safeguards, or implementation timelines before the deadline.
• Plan Supply Chain Logistics: Ensure that commercial manufacturing and distribution strategies align with the supply obligations for qualifying rare disease drugs outlined in the draft measures.

Final Thoughts

The introduction of these draft measures marks a pivotal shift for international developers entering the Chinese pharmaceutical landscape. By establishing concrete pathways for pediatric and rare disease therapies, the NMPA rewards genuine clinical innovation while tying protection to rigorous supply obligations.

To navigate this environment, pharmaceutical teams should audit their pipeline portfolios early and factor exclusivity applications directly into their registration roadmaps. Furthermore, with the consultation window open through November 18, 2026, sponsors have a crucial opportunity to engage directly with regulators.

For support with China regulatory strategy, market entry planning, and technical feedback on proposed NMPA requirements, contact Cisema today.

About the Author: Stefanie Fasshauer

Stefanie Fasshauer is Vice President, BioPharma at Cisema, with over 20 years of international experience in the life sciences industry. She advises pharmaceutical and biotechnology companies on global drug development, regulatory strategy, and market expansion across Europe, the US, and Asia-Pacific. Her background combines senior industry leadership with contributions to regulatory science, professional education, and international knowledge exchange through collaborations with academic institutions and industry organizations.

Further Information

• Explore Cisema’s services for pharmaceutical consulting in China.
• Read Cisema’s article: China’s 2026 Drug Regulation Revision: How State Council Decree No.828 Elevates Innovation and Tightens Lifecycle Accountability.

References

• NMPA Public Consultation on the Implementation Measures on Drug Market Exclusivity (Draft for Comments)